(1) Dr Renu Bhatia will be appointed as the Senior and Lead Independent Non-executive Director, and appointed on the Nomination Committee as the chairman; (2) Dr Chaohong Hu will be appointed as the ...
Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year ...
A 2026 consumer research report examining Paingone Plus TENS pen searches, portable TENS pain relief device claims, FDA clearance status, published nerve stimulation therapy research, doctor ...
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved, it has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the FDA for use ...
Q4 2025 Adjusted EBITDA of $508,500 was an increase of 23.1% over Q4 2024 Adjusted EBITDA of $412,947 and a decrease of 24.2% over Q3 2025 Adjusted EBITDA of $670,706.
It is anticipated that the Shares will be delisted from the Toronto Stock Exchange (“ TSX ”) and the Nasdaq Capital Markets (“ NASDAQ ”) and that the Company will cease to be a reporting issuer in all ...
Atea will host a live conference call and audio webcast today, Thursday, March 5, 2026, at 4:30 p.m. ET, to report financial results for the fourth quarter and full year 2025 ended December 31, 2025, ...
The Company will provide a hard copy of its annual report on Form 20-F, including its audited financial statements, free of charge, to its shareholders upon request. Request should be directed in ...
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ...
The Debenture Units were issued at a price of $50,000 per Debenture Unit and each such Debenture Unit was comprised of (i) one unsecured convertible debenture (a “New Debenture”) in the principal ...
Through Omada’s GLP-1 Flex Care offering, employers gain a new flexible option to connect employees with anti-obesity medication, virtual care, and lifestyle support ...
Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: All amounts are in United States dollars unless otherwise specified.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results